Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IKAROS family zinc finger 4 (IKZF4), also known as Eos, is a member of the Ikaros family of zinc finger transcription factors, characterized by multiple C2H2-type zinc finger domains[4][9][6]. IKZF4 is predominantly expressed in immune cells, especially lymphocytes, and is active in the development and regulation of hematopoietic and immune cell lineages, including T cell differentiation[3][4]. Additionally, IKZF4 is involved in the developing nervous system, where it regulates temporal cell fate specification in retinal progenitors and is essential for both cone photoreceptor and Müller glia production via modulation of genes like Pou2f2 and Notch pathway effectors[2]. IKZF4 acts as a DNA-binding transcription factor, binding to GGAA-containing motifs in target gene regulatory regions[1][2]. Dysregulation of Ikaros family members has been implicated in cancer and immune disorders, but IKZF4 is not currently a direct pharmaceutical target in clinical practice[3][7][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on IKAROS family zinc finger 4 (IKZF4).